Connect with us

Health

Study Shows Organovo’s Drug Dramatically Reduces Liver Fat in NASH, According to ET HealthWorld

Published

on

Organovo's drug significantly reduces liver fat in NASH study, ET HealthWorld

London: Organovo Holdings’ experimental drug, FXR314, showed promising results in reducing liver fat in patients with non-alcoholic steatohepatitis (NASH). The mid-stage study reported a reduction in liver fat by as much as 22.8%, sparking optimism in the potential of the drug to enter the multi-billion dollar NASH treatment market. The small biotech firm’s shares surged by 44% to $1.45 following the data release.

NASH, previously known as metabolic function-associated steatohepatitis (MASH), is characterized by an accumulation of fat in the liver, leading to inflammation and scarring. The global market for NASH treatments is projected to exceed $16 billion by 2030, according to Vision Research Reports. Last month, the U.S. health regulator approved Madrigal Pharmaceuticals’ Rezdiffra as the first treatment for this condition.

In a 16-week study involving 214 patients, those who received 3 mg of FXR314 saw an average 22.8% reduction in liver fat, compared to 6.1% in the placebo group. Organovo stated that the drug also improved liver function without exacerbating scarring or fibrosis, and was well-tolerated by patients. Detailed findings of the study are expected to be presented at an upcoming conference.

The positive outcome of the FXR314 study has raised hopes for a potential breakthrough in NASH treatment, addressing a critical medical need for patients with this liver disease. Organovo’s successful mid-stage trial marks a significant advancement in the field of liver health research, with implications for future drug development and patient care.

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Trending